Releasing a drug inside a cell's recycling compartment is one step in delivery. Some released drug forms also need transport into the rest of the cell before they can act.
Primary experiments identified SLC46A3 as a transporter involved in movement of noncleavable maytansine-conjugate catabolites from lysosomes to the cytoplasm. Reducing SLC46A3 affected the studied maytansine conjugates, while the tested MMAF conjugates behaved differently. Transporter dependence is therefore specific to the released species and construct. It is a mechanistic research finding, not a validated clinical selection test for every antibody-drug conjugate.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares DM1, Trastuzumab emtansine, Antibody-drug conjugate (ADC).
Shares Antibody internalization and intracellular trafficking, Evidence from measurement to patient benefit, Antibody-drug conjugate (ADC).
Shares Antibody internalization and intracellular trafficking, Evidence from measurement to patient benefit.
Shares MMAF, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, Antibody-drug conjugate (ADC).
Shares Evidence from measurement to patient benefit, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/